| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 143 | 2020 |
| Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐or immunotherapy TA Fox, E Troy‐Barnes, AA Kirkwood, WY Chan, JW Day, SJ Chavda, ... British journal of haematology 191 (2), 194-206, 2020 | 78 | 2020 |
| Prevalence and timing of TP53 mutations in del (17p) myeloma and effect on survival M Chin, JI Sive, C Allen, C Roddie, SJ Chavda, D Smith, P Blombery, ... Blood cancer journal 7 (9), e610-e610, 2017 | 62 | 2017 |
| Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+ PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma N Alrasheed, L Lee, E Ghorani, JY Henry, L Conde, M Chin, ... Clinical Cancer Research 26 (13), 3443-3454, 2020 | 46 | 2020 |
| Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study A Cowan, F Ferrari, SS Freeman, R Redd, H El-Khoury, J Perry, V Patel, ... The Lancet Haematology 10 (3), e203-e212, 2023 | 22 | 2023 |
| Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes M Bustoros, S Anand, R Sklavenitis-Pistofidis, R Redd, EM Boyle, ... Nature communications 13 (1), 3449, 2022 | 14 | 2022 |
| Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly … K Yong, W Wilson, RM de Tute, M Camilleri, K Ramasamy, M Streetly, ... The Lancet Haematology 10 (2), e93-e106, 2023 | 12 | 2023 |
| Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease … WY Chan, L Howells, W Wilson, E Sanchez, L Ainley, SJ Chavda, ... British Journal of Haematology 196 (3), e21, 2022 | 12 | 2022 |
| Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma S Gooding, N Ansari-Pour, M Kazeroun, K Karagoz, A Polonskaia, ... Blood, The Journal of the American Society of Hematology 140 (16), 1816-1821, 2022 | 9 | 2022 |
| Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study M Camilleri, M Cuadrado, E Phillips, W Wilson, R Jenner, G Pang, ... British Journal of Haematology 193 (4), 750-760, 2021 | 9 | 2021 |
| Efficacy and safety of carfilzomib at 56mg/m2 with cyclophosphamide and dexamethasone (K56Cd) in newly diagnosed multiple myeloma patients followed by ASCT or K56Cd … K Yong, R Popat, W Wilson, G Pang, R Jenner, RM De Tute, K Ramasamy, ... Blood 134, 861, 2019 | 9 | 2019 |
| Increased immune-regulatory receptor expression on effector T cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma L Lee, N Alrasheed, G Khandelwal, E Fitzsimons, H Richards, W Wilson, ... Frontiers in immunology 12, 618610, 2021 | 8 | 2021 |
| Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly … K Yong, M Camilleri, W Wilson, K Ramasamy, MJ Streetly, J Sive, ... Journal of Clinical Oncology 39 (15_suppl), 8000-8000, 2021 | 5 | 2021 |
| Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease H Leng, H Zhang, L Li, S Zhang, Y Wang, SJ Chavda, D Galas-Filipowicz, ... Nature Communications 13 (1), 7868, 2022 | 4 | 2022 |
| Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression. L Ainley, M Camilleri, SJ Chavda, A McMillan, L Lee, R Popat, F Sillito, ... British Journal of Haematology 196 (6), 2022 | 4 | 2022 |
| Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy WY Chan, E Sanchez, SJ Chavda, CSY Lecat, L Ainley, K Xu, ... British Journal of Haematology 194 (5), 857, 2021 | 3 | 2021 |
| DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation L Ainley, SJ Chavda, N Counsell, S Cheesman, F Newrick, J Horder, ... British Journal of Haematology 192 (3), e73-e77, 2021 | 3 | 2021 |
| Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations SJ Chavda, R Pocock, S Cheesman, KM Lee, E Dowling, DJB Marks, ... British Journal of Haematology, 2020 | 3 | 2020 |
| A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1 SJ Chavda, PM Maciocia, P Mesiri, N Counsell, J Kothari, A Bird, ... British journal of haematology 185 (2), 350-353, 2019 | 2 | 2019 |
| Ascites SJ Chavda, SL Bloom British Journal of Hospital Medicine 76 (2), C23-C27, 2015 | 2 | 2015 |
